FidoCure
Precision Medicine for Canine Cancer

• DNA sequencing diagnostic in a CLIA certified lab
• Telemedicine-enabled clinical guidance
• Access to targeted therapy, FDA approved for humans
• Administered orally at your clinic or the patient’s home
• Complies with USP 800
Case Study

Gracie: Significant Lesion Reduction

Dr. Robert Proietto, VMD, MS treated Gracie, a 6 year old American pitbull mix, who was diagnosed with soft tissue sarcoma and thoracic metastasis. After starting Fidocure™ enabled targeted therapy, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.
Gracie Tumor - Before and After
Case Study

Gracie: Significant Lesion Reduction

Dr. Robert Proietto, VMD, MS treated Gracie, a 6 year old American pitbull mix, who was diagnosed with soft tissue sarcoma and thoracic metastasis. After starting Fidocure™ enabled targeted therapy, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.
Gracie Tumor - Before and After

Differentiate your practice with advanced, personalized canine cancer care.

The options to treat canine cancer are often limited, while pet parents are increasingly willing to do more for their dogs. FidoCure enables veterinarians to differentiate their practice with advanced, personalized canine cancer care, previously only available for humans.

Human Oncology

1.6M New Annual Cases

84+ Targeted Therapies in use

84 targeted therapies humans

Veterinary Oncology

6M New Annual Cases

1 Targeted Therapy

one targeted therapy canines
84 targeted therapies humans
one targeted therapy canines

All Cancers are Eligible for FidoCure

FidoCure - All Cancer

• Genomic diagnostic test to uncover possible tumor-associated changes

• Access to targeted therapeutics as a treatment option

• Oral therapy is easy to administer at home

• An alternative to DNA-damaging chemotherapy or radiation

• All our therapeutic suggestions are for FDA approved human drugs

FidoCure for Mast Cell Tumors

• Many mast cell tumors are c-Kit driven

• Access to a c-Kit targeted therapy as another option for drug-refractory cancers

• An alternative to DNA-damaging chemotherapy or radiation

• Oral therapy is easy to administer at home

• FDA approved human drug

FidoCure for Transitional Cell Carcinoma

• Many transitional cell carcinomas are BRAF+

• Access to a EGFR/HER2 and/or MEK targeted therapy suited to treatment of TCC

• An alternative to DNA-damaging chemotherapy or radiation

• Oral therapy is easy to administer at home

• FDA approved human drug

FidoCure by Tumor Type

FidoCure Case Breakdown
by Tumor Type

FidoCure Case Breakdown by Tumor Type

FidoCure by Tumor Type
White Paper

Fidocure Precision Medicine White Paper

Read an in-depth explanation of FidoCure’s approach to precision medicine, including molecular profiling, biomarkers, and targeted therapy.
White Paper

Fidocure™ Precision Medicine White Paper

Read an in-depth explanation of FidoCure’s approach to precision medicine, including molecular profiling, biomarkers, and targeted therapy.

Why Offer FidoCure to Families

Interview with Dr. Gerald Post
Almost every cancer in humans is treated with one or a number of different targeted therapies. We believe that that’s going to be the case for veterinary oncology in the near future.

— Dr. Gerald Post · DVM MEM DACVIM
Chief Veterinary Officer, One Health Company

Hundreds of dogs have benefitted from FidoCure this year.

Dr. Aarti Sabhlok
Dr. Aarti Sabhlok

DVM, DACVIM

“It narrows it down a little bit and gives me additional options and sometimes they’re drugs I wouldn’t have thought to use for that particular patient or that particular cancer.”

Dr. Brooke Fowler
Dr. Brooke Fowler

DVM MS DACVIM

“FidoCure™ is advancing the field of veterinarian oncology by providing the technology to help vet oncologists pinpoint the genetic mutation that may be causing a dog's cancer and providing treatment alternatives that use the latest advances in human oncology.”

Dr Rob Proietto
Dr. Rob Proietto

VMD, MS

“All of our cases have done tremendous so far so I am hopeful for a long quality of life ahead”